Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Gross Profit: 2020-2024

Historic Gross Profit for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $166.2 million.

  • Xeris Biopharma Holdings' Gross Profit rose 55.83% to $63.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.0 million, marking a year-over-year increase of 47.63%. This contributed to the annual value of $166.2 million for FY2024, which is 22.89% up from last year.
  • Xeris Biopharma Holdings' Gross Profit amounted to $166.2 million in FY2024, which was up 22.89% from $135.3 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Gross Profit registered a high of $166.2 million during FY2024, and its lowest value of $11.1 million during FY2020.
  • Moreover, its 3-year median value for Gross Profit was $135.3 million (2023), whereas its average is $129.7 million.
  • Data for Xeris Biopharma Holdings' Gross Profit shows a peak YoY spiked of 226.57% (in 2021) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' Gross Profit (Yearly) stood at $11.1 million in 2020, then spiked by 226.57% to $36.3 million in 2021, then skyrocketed by 141.55% to $87.6 million in 2022, then skyrocketed by 54.39% to $135.3 million in 2023, then rose by 22.89% to $166.2 million in 2024.